Table 3.
Molecular Hydrogen Use in Experimental TBI
Inhaled gas study | Form | Timing after injury (duration) | TBI type (severity) | Subject | Outcomes assessed | Findings |
---|---|---|---|---|---|---|
Hydrogen gas63 | Hydrogen rich water (0.63-0.82 mmol/L) IP | 5 min (IP injection daily for 1 day, 2 days, 3 days, 14 days duration) | Controlled cortical impact (moderate) | Rats | Whole–brain (inflammatory cytokines), hippocampus (Iba-1, synapsin I) | Reduced TNF-α, IL-1β, HGMB1, Iba-1, inflammatory metabolites on MRS; increased IL-10, synapsin 1, improved cognitive function |
Hydrogen gas67 | Inhaled 2% H2 | 30 min (4.5 h) | Controlled cortical impact (moderate) | Rats | Pericontusional microRNA-21 | Reduced microRNA-21, cerebral edema, contusion volume, blood–brain barrier permeability, oxidative stress; improved cognitive function |
Hydrogen gas64 | Inhaled 2% H2 | Immediately post-injury (5 h) | Controlled cortical impact (moderate) | Rats | Cerebral cortex Injury | Reduced blood–brain barrier permeability, cerebral edema, lesion volume, improved cognitive function, reduced markers of oxidative stress |
TBI, traumatic brain injury; IP, intraperitoneal; TNF, tumor necrosis factor; HGMBI1, High mobility group box 1; MRS, magnetic resonance spectroscopy.